Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548399 | 1.00 | PIM1 (1.00) | PIM1ALDH1A1ENPP2PPARGKDM4E | |
| SCHEMBL2547330 | 0.87 | PIM1 (0.77) | PIM1ALDH1A1ENPP2PPARGKDM4E | |
| SCHEMBL2547331 | 0.87 | PIM1 (0.77) | PIM1ALDH1A1ENPP2PPARGKDM4E | |
| SCHEMBL6691625 | 0.77 | PPARG (0.69) | PIM1ALDH1A1ENPP2PPARGMEN1 | |
| SCHEMBL6691628 | 0.77 | PPARG (0.69) | PIM1ALDH1A1ENPP2PPARGMEN1 | |
| SCHEMBL2510653 | 0.76 | ALDH1A1 (0.72) | PIM1ALDH1A1KDM4EMEN1HTT | |
| SCHEMBL2510655 | 0.76 | ALDH1A1 (0.72) | PIM1ALDH1A1KDM4EMEN1HTT | |
| SCHEMBL31228666 | 0.76 | PIM1 (0.61) | PIM1ENPP2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20534356 | 0.75 | AKR1B1 (0.78) | AKR1B1 | |
| SCHEMBL20534357 | 0.75 | AKR1B1 (0.78) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885ALDH1A1 3546/4885ENPP2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.